Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Overexpression of ATP-binding cassette transporter ABCG2 as a potential mechanism of acquired resistance to vemurafenib in BRAF(V600E) mutant cancer cells.

Biochemical pharmacology - 1 Feb 2013

Wu Chung-Pu, Sim Hong-May, Huang Yang-Hui, Liu Yen-Chen, Hsiao Sung-Han, Cheng Hsing-Wen, Li Yan-Qing, Ambudkar Suresh V, Hsu Sheng-Chieh

Abstract excerpt

Melanoma is the most serious type of skin cancer with a high potential for metastasis and very low survival rates. The discovery of constitutive activation of the BRAF kinase caused by activating BRAF(V600E) kinase mutation in most melanoma patients led to the discovery of the first potent BRAF(V...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to ATP Binding Cassette Transporter, Subfamily B
Share to ATP Binding Cassette Transporter, Subfamily B, Member 1

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ATP Binding Cassette Transporter, Subfamily G, Member 2

Share to ATP-Binding Cassette Transporters

Share to Indoles

Share to Multidrug Resistance-Associated Proteins

Share to Sulfonamides

Share to Vemurafenib

Source

Open in PubMed Open full text

Identifiers

PMID: 23153455
DOI: 10.1016/j.bcp.2012.11.003
PMCID: PMC3553236

Genes

BRAF
ABCG2
ABCB1
ABCC1

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-23153455-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Overexpression of ATP-binding cassette transporter ABCG2 as a potential mechanism of acquired resistance to vemurafenib in BRAF(V600E) mutant cancer cells.PMID 23153455Read ↗

Differential expression of ABCB5 in BRAF inhibitor-resistant melanoma cell linesSemantic proximity Read ↗

Vemurafenib: an evidence-based review of its clinical utility in the treatment of metastatic melanoma.Semantic proximity Read ↗

Association between acquired resistance to PLX4032 (vemurafenib) and ATP-binding cassette transporter expression.Semantic proximity Read ↗

Vemurafenib.Semantic proximity Read ↗

The discovery of vemurafenib for the treatment of BRAF-mutated metastatic melanoma.Semantic proximity Read ↗

Vemurafenib: the road to personalized medicine in melanoma.Semantic proximity Read ↗

Acquired and intrinsic resistance to vemurafenib in BRAF <sup>V600E</sup> -driven melanoma brain metastasesSemantic proximity Read ↗

Vemurafenib: a new treatment for BRAF-V600 mutated advanced melanomaSemantic proximity Read ↗

ABCB8 Mediates Doxorubicin Resistance in Melanoma Cells by Protecting the Mitochondrial GenomeSemantic proximity Read ↗

Vemurafenib for the treatment of BRAF mutant metastatic melanoma.Semantic proximity Read ↗

Characterization of Vemurafenib-Resistant Melanoma Cell Lines Reveals Novel Hallmarks of Targeted Therapy ResistanceSemantic proximity Read ↗

Vemurafenib in Chinese patients with BRAFV600 mutation-positive unresectable or metastatic melanoma: an open-label, multicenter phase I study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.